Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.

Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat

Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.

HEXO Soars: Stock Adds 7.9% in Session

HEXO saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Here's Why Abbott (ABT) is a Great Momentum Stock to Buy

Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.

Boston Scientific (BSX) Hurt by Product Recall, Conversion

Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.

Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up

Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.

Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio

Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

Cardinal Health's (CAH) fiscal second-quarter results reflect strong segmental performance.

Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2

Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q1

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

Is (ABT) Outperforming Other Medical Stocks This Year?

Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows

Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Up Y/Y

Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance in the Network Solutions segment.

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.

AmerisourceBergen (ABC) Q1 Earnings & Revenues Beat Estimates

AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.

Align Technology (ALGN) Beats on Q4 Earnings, Margins Up

Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.

Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up

Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.